NEWS

15/09/2009

Dr Sharon O'Kane to leave Renovo at AGM

Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring, today announces that Dr. Sharon O’Kane, Executive Director, Chief Scientific Officer and Co-Founder will be leaving the Company with effect from the next Annual General Meeting on 10th February 2010, to pursue other business interests. Dr O'Kane has helped to build the success of Renovo since its foundation.

Dr Sharon O’Kane commented: “I have greatly enjoyed helping to build Renovo from its foundation 10 years ago through to the successful public company it is today. I intend to use this experience to help start and build other companies and to take up some Non-Executive director positions. I am confident that Renovo has a bright future which I will follow with interest.”

Mr Rodger Pannone, Chairman of Renovo, said: “The Board would like to thank Sharon for her significant contribution to the success of the business over the last 10 years, during which time Renovo has developed from a small early stage private company to a larger public entity with a late stage pipeline of drugs for the prevention and reduction of scarring. Whilst we will be extremely sorry to see Sharon leave, we understand that she wishes to put her experience to use in growing and advising other companies. We wish her well for the future.”